BC Week In Review | Nov 7, 2011
Clinical News

DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System: Completed Phase I enrollment

Elixir completed enrollment of 15 patients with de novo coronary artery lesions in the open-label, international Phase I DESolve I trial evaluating the DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System. Elixir has an exclusive, worldwide...
Items per page:
1 - 1 of 1